150 related articles for article (PubMed ID: 10822468)
21. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b.
Costa da Cunha CS; Lebbe C; Rybojad M; Agbalika F; Ferchal F; Rabian C; Vignon-Pennamen MD; Calvo F; Morel P
Arch Dermatol; 1996 Mar; 132(3):285-90. PubMed ID: 8607632
[TBL] [Abstract][Full Text] [Related]
22. Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.
Rokx C; van der Ende ME; Verbon A; Rijnders BJ
Clin Infect Dis; 2013 Nov; 57(10):1497-9. PubMed ID: 23912848
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma.
Trattner A; Reizis Z; David M; Ingber A; Hagler J; Sandbank M
Br J Dermatol; 1993 Nov; 129(5):590-3. PubMed ID: 8251357
[TBL] [Abstract][Full Text] [Related]
24. Interferon treatment of renal cell carcinoma. Current status and future prospects.
Krown SE
Cancer; 1987 Feb; 59(3 Suppl):647-51. PubMed ID: 10822464
[TBL] [Abstract][Full Text] [Related]
25. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
26. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
28. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
de Wit R; Bakker PJ; Danner SA; Goudsmit J; Veenhof KH
Int J STD AIDS; 1990 Jul; 1(4):256-8. PubMed ID: 2088534
[TBL] [Abstract][Full Text] [Related]
29. Classic Kaposi's sarcoma: low-dose interferon alfa treatment.
Tur E; Brenner S
Dermatology; 1998; 197(1):37-42. PubMed ID: 9693183
[TBL] [Abstract][Full Text] [Related]
30. Criteria for use of interferon alfa-2a or interferon alfa-2b for selected indications in adults.
Am J Hosp Pharm; 1994 Apr; 51(8):1030-3. PubMed ID: 7518650
[No Abstract] [Full Text] [Related]
31. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients.
Jones GJ; Itri LM
Cancer; 1986 Apr; 57(8 Suppl):1709-15. PubMed ID: 3948143
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of 5 patients affected by Kaposi's sarcoma and AIDS with recombinant interferon alfa-2A (roferon-A)].
Lopez Bran E; Aguilar R; Marron JA; Figueredo MA; Garcia Ruiz JM
Med Cutan Ibero Lat Am; 1989; 17(4):269-73. PubMed ID: 2693866
[TBL] [Abstract][Full Text] [Related]
35. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trials of alpha-interferon alone or in combination with zidovudine as maintenance therapy following induction chemotherapy in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Gill PS
Semin Oncol; 1991 Oct; 18(5 Suppl 7):53-7. PubMed ID: 1719642
[TBL] [Abstract][Full Text] [Related]
37. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
[TBL] [Abstract][Full Text] [Related]
38. Interferon alfa-2a tretinoin in patients with metastatic renal cell carcinoma: a pilot study.
Paule B; Bonhomme-Faivre L; Rudant E; Ferrière F
Am J Health Syst Pharm; 1997 Jan; 54(2):190-2. PubMed ID: 9117809
[No Abstract] [Full Text] [Related]
39. A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum.
Obenauer-Kutner LJ; Jacobs SJ; Kolz K; Tobias LM; Bordens RW
J Immunol Methods; 1997 Aug; 206(1-2):25-33. PubMed ID: 9328565
[TBL] [Abstract][Full Text] [Related]
40. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study.
Shepherd FA; Beaulieu R; Gelmon K; Thuot CA; Sawka C; Read S; Singer J
J Clin Oncol; 1998 May; 16(5):1736-42. PubMed ID: 9586886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
